Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda
NICE approval is for first-line treatment of intermediate and advanced renal cell carcinoma
Read More
Tag: Kisplyx
NICE u-turn backs combo for kidney cancer
In a turnaround from its earlier position, the National Institute for Health and Care Excellence is now endorsing NHS funding for Eisai’s Kisplyx plus everolimus for kidney cancer.
Read More
NICE turns down kidney cancer drugs
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Read More
US, EU filings for Eisai’s lenvatinib in liver cancer
Eisai has filed its anticancer drug lenvatinib for liver cancer on both sides of the Atlantic as it seeks to expand the drug’s list of approved uses.
Read More
Eisai’s Kisplyx approved in EU for kidney cancer
The European Commission has stamped its approval on the use of Eisai’s Kisplyx to treat advanced kidney cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
